Centogene

171 articles with Centogene

• CENTOGENE Appoints Ian Rentsch as Chief Commercial Officer and General Manager - Pharma

  3/9/2023

  Centogene N.V. today announced the appointment of Ian Rentsch as Chief Commercial Officer and General Manager - Pharma, who will join the Company on March 15, 2023.

• CENTOGENE to Participate in Upcoming Conferences in March

  3/8/2023

  Centogene N.V. today announced its conference schedule for March 2023.

• In the Lead-Up to Rare Disease Day, CENTOGENE Expands Observational Study to Advance the Genetic Understanding of Frontotemporal Dementia (FTD)

  2/21/2023

  Centogene N.V., the essential life science partner for data-driven answers in rare and neurodegenerative diseases, announced that it has extended and expanded the observational EFRONT Study to advance the genetic understanding of frontotemporal dementia.

• CENTOGENE to Participate in Upcoming Conferences in February in the Lead Up to Rare Disease Day

  2/7/2023

  Centogene N.V. today announced its partnering conference schedule for February 2023, with a focus on rare and genetic diseases in the lead up to Rare Disease Day (RDD) on February 28th.

• CENTOGENE Regains Compliance With Nasdaq Listing Requirements - February 07, 2023

  2/7/2023

  Centogene N.V. announced that it has received a notification from the Nasdaq Stock Market LLC Listing Qualifications Department informing the Company that it has regained compliance with the minimum bid price requirement for continued listing on the Nasdaq under Nasdaq Listing Rule 5450.

• Twist Bioscience and CENTOGENE Launch Three Panels to Advance Rare Disease and Hereditary Cancer Research and Support Diagnostics

  1/10/2023

  Twist Bioscience Corporation and Centogene N.V. today announced the launch of three next-generation sequencing (NGS) target enrichment panels to support rare disease and hereditary cancer research and support diagnostics.

• Premier Research and CENTOGENE Launch Strategic Partnership to Accelerate and De-Risk Rare Disease Clinical Development

  1/9/2023

  Premier Research and Centogene N.V. have announced a strategic partnership to provide end-to-end support in rare disease clinical trials.

• CENTOGENE and Denali Therapeutics Extend World’s Largest Observational Study on Parkinson’s Disease Genetics

  1/9/2023

  Centogene N.V., the essential life science partner for data-driven answers in rare and neurodegenerative diseases, announced that it has extended the Rostock International Parkinson's Disease Study to recruit and genetically test additional patients over the next few years.

• CENTOGENE Announces Its Attendance at the 41st Annual J.P. Morgan Healthcare Meeting and Fierce JPM Week in San Francisco

  12/28/2022

  Centogene N.V. announced that its management team, including Chief Executive Officer Kim Stratton, will be attending the 41st Annual J.P. Morgan Healthcare Meeting, on January 9-12, 2023, in San Francisco, U.S.

• CENTOGENE Reports Second Quarter and First Half 2022 Financial Results

  12/22/2022

  Centogene N.V.(Nasdaq:CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced unaudited financial results for the second quarter and first half ended June 30, 2022 and updated its fiscal year 2022 financial outlook.

• CENTOGENE Receives Nasdaq Non-Compliance Notice

  12/16/2022

  Centogene N.V. has received notification from the Nasdaq Stock Market LLC Listing Qualifications Department that it was not in compliance with the minimum bid price requirement set forth in Nasdaq Rule 5450 since the closing bid price for the Company's common shares listed on Nasdaq was below US$1.00 for 30 consecutive business days.

• CENTOGENE to Participate in Upcoming Conferences in December 2022

  12/1/2022

  Centogene N.V., the essential life science partner for data-driven answers in rare and neurodegenerative diseases, announced its conference schedule for December 2022.

• CENTOGENE Announces Changes to Supervisory Board, Including Appointment of Mary Sheahan

  11/21/2022

  Centogene N.V. today announced the appointment of Mary Sheahan as a member of the Supervisory Board, to be confirmed at the Company’s next General Meeting of Shareholders.

• CENTOGENE to Participate in Upcoming Conferences in November 2022

  11/10/2022

  Centogene N.V., the essential life science partner for data-driven answers in rare and neurodegenerative diseases, announced its conference schedule for November 2022.

• CENTOGENE Launches Rare and Neurodegenerative Disease Biodata Network

  11/3/2022

  Centogene N.V. announced the global launch of its Biodata Network, a portfolio of data-driven partnering solutions, including Biodata Licenses and Insight Reports, for biopharma and research institutions.

• CENTOGENE to Participate in Upcoming Partnering Conferences in October 2022

  10/6/2022

  Centogene N.V., the commercial-stage essential biodata life science partner for rare and neurodegenerative diseases, announced its partnering conference schedule for October 2022.

• CENTOGENE Reaches 12,500 Patient Milestone in World’s Largest Observational Study on Parkinson’s Disease Genetics

  10/3/2022

  Centogene N.V., the commercial-stage essential biodata life science partner for rare and neurodegenerative diseases, announced reaching a significant milestone with the recruitment and genetic testing of 12,500 participants in the Rostock International Parkinson's Disease Study.

• CENTOGENE to Present at Upcoming Investor & Partnering Conferences in September 2022

  9/1/2022

  Centogene N.V., the commercial-stage essential biodata life science partner for rare and neurodegenerative diseases, announced its investment and partnering conference schedule for September 2022.

• CENTOGENE Reports First Quarter 2022 Financial Results

  7/15/2022

  Centogene N.V. (Nasdaq: CNTG), the commercial-stage essential biodata life science partner for rare and neurodegenerative diseases, today announced financial results for the first quarter ending March 31, 2022, reaffirmed guidance, and provided a business update.

• CENTOGENE Announces Shareholder Approval of All Resolutions at 2022 Annual General Meeting

  6/27/2022

  Centogene N.V., the commercial-stage, essential biodata life science partner for rare and neurodegenerative diseases, announced the voting results of the Company’s Annual General Meeting.